In Vitro Antimicrobial Activity of Doripenem, a New Carbapenem

Abstract

The doripenem MICs at which 90% of the tested strains were inhibited ranged from 0.03 to 1 g/ml for 10 species of Enterobacteriaceae (n ‫؍‬ 351), from 0.03 to 0.12 g/ml for oxacillin-susceptible staphylococci (n ‫؍‬ 119), from 4 to 32 g/ml for oxacillin-resistant staphylococci (n ‫؍‬ 64), from <0.008 to 0.06 g/ml for penicillin-susceptible streptococci (n ‫؍‬ 132), and from 1 to 4 g/ml for penicillin-resistant streptococci (n ‫؍‬ 51). Overall, doripenem demonstrated in vitro activity similar to that of meropenem against gram-negative pathogens and to that of imipenem against gram-positive pathogens.

Open-Label Study To Evaluate the Single-Dose Pharmacokinetics, Safety, and Tolerability of Doripenem in Infants Less than 12 Weeks in Chronological Age

“…Doripenem for injection is a sterile, synthetic, parenteral antibiotic of the carbapenem class of ␤-lactam antibiotics with broadspectrum, potent, antibacterial activity against aerobic and anaerobic Gram-negative and Gram-positive pathogens, including extended-spectrum ␤-lactamase-producing Enterobacteriaceae and Pseudomonas aeruginosa (11)(12)(13)(14)(15)(16)(17)(18)(19). It exerts its activity by targeting penicillin-binding proteins to inhibit the biosynthesis of the bacterial cell wall.…”

In Vitro Activity of Doripenem (S-4661) against Multidrug-Resistant Gram-Negative Bacilli Isolated from Patients with Cystic Fibrosis

“…Doripenem is a carbapenem in clinical development for serious bacterial infections. It has potent in vitro activity against a wide range of gram-positive and gram-negative clinical isolates (2,5,11) and in vivo efficacy in various animal models (10). We studied the in vitro activity of doripenem against 600 multidrugresistant clinical strains of P. aeruginosa and B. cepacia complex isolated from patients with CF and compared its activity with seven other conventional antipseudomonal antibiotics.…”

Fluoroquinolone Enhances the Mutation Frequency for Meropenem-Selected Carbapenem Resistance in Pseudomonas aeruginosa , but Use of the High-Potency Drug Doripenem Inhibits Mutant Formation

“…b DRPM is a new carbapenem that has been developed by Shionogi Pharmaceuticals, Osaka, Japan) (7,8,19). Abbreviations for the other antibiotics used are as follows: CAZ, ceftazidime; PIPC, piperacillin; GM, gentamicin; CPFX, ciprofloxacin; and OFLX, ofloxacin.…”